You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

Clinical Advances in

Quality Improvement of Type 2 Diabetes: Improving Patient Outcomes

Glycemic control remains the cornerstone of management of type 2 diabetes (T2D) as it plays a vital role in preventing or delaying the onset and progression of complications. Individualizing therapeutic goals and using modern antihyperglycemic agents when appropriate is crucial to safe and effective management of T2D. These educational activities aim to increase awareness of cardiovascular outcomes data and provide practical strategies to help patients achieve T2D goals using combination therapy.

Supported by


CME Activities

Quality Focused T2D Management

Clinical Application of Modern T2D Agents

Conference Coverage

Polling Question

How have you interpreted the data from LEADER and EXSCEL?
I often recommend liraglutide over exenatide ER to most of my patients with T2D and established CVD if tolerated
The results from LEADER cannot be extrapolated to patients with T2D without CVD
I am more comfortable using weekly exenatide ER in patients with T2D who have CV risk factors if tolerated
Differences in trial designs, patient populations, and treatment persistence may explain the differences in outcomes in LEADER and EXSCEL

Related Resources

Downloadable Slide Kit

Cardiovascular Outcome Trials and Real-World Data

Review recently published CV outcome trial data on antihyperglycemic agents, including real-world data on SGLT2 inhibitors.


Clinical Articles

ADA Standards of Medical Care in Diabetes, 2017  

AACE/ACE Comprehensive Diabetes Management Algorithm, 2017  

Position Statement of the ADA and the EASD, 2015  

Patient Resources

Related Links

Steering Committee

Anne L. Peters, MD

Steering Committee Chair

Professor, Keck School of Medicine of the University of Southern California; Director, USC Clinical Diabetes Programs, University of Southern California, Los Angeles, California

John E. Anderson, MD

The Frist Clinic, Nashville, Tennessee

Lawrence Blonde, MD

Director, Ochsner Diabetes Clinical Research Unit, Frank Riddick Diabetes Institute, Department of Endocrinology, Ochsner Medical Center, New Orleans, Louisiana

Daniel Einhorn, MD

Clinical Professor, University of California at San Diego; Medical Director, Scripps Whittier Diabetes Institute, La Jolla, California

Julio Rosenstock, MD

Clinical Professor of Medicine, University of Texas Southwestern Medical Center; Director, Dallas Diabetes and Endocrine Center at Medical City, Dallas, Texas

Carol H. Wysham, MD

Clinical Professor of Medicine, University of Washington, Spokane, Washington